Diabetic cardiopathy: Pathomechanism, diagnostic and therapy;Diabetische kardiopathie: Pathomechanismen, diagnostik und therapie

Internist

Volumn 44, Issue 7, 2003, Pages 806-818

  Tschope C ^a   Schultheiss, H P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Diabetes mellitus; Diabetic cardiomyopathy; Diastolic dysfunction; Endothelial dysfunction; Myocardial infarction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE ANTAGONIST; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METFORMIN; METOPROLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEINASE INHIBITOR; PYRIDOXAMINE; RAMIPRIL; RUBOXISTAURIN; THIAZIDE DIURETIC AGENT;

ACUTE HEART INFARCTION; ALGORITHM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIAGNOSTIC APPROACH ROUTE; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; MORTALITY; MUSCLE HYPERTONIA; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 0042315255     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-0947-z     Document Type: Review

References (53)

1. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO (2002) Prevention Conference VI: Diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 105: 2231-2239
2. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-44
4. Rösen P (2002) Endotheliale Dysfunktion: ein Synonym für funktionelle Atherosklerose. J Kardiol 9: 556-562
5. Rösen P, Ferber P, Tschöpe D (2001) Macrovascular disease in diabetes: current status. Exp Clin Endocrinol Diabetes 109 (Suppl 2): S474-486
6. Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G (2002) German Society of Cardiology-Heart- and Vascular Research Recommendations for comprehensive risk reduction for patients with coronary heart disease, vascular diseases and diabetes. Distributed by the leadership of the German Society of Cardiology-Heart- and Vascular Research. Produced by request of the Committee of Clinical Cardiology bythe Prevention Project Group. Z Kardiol 91 (Suppl 2): 61-62
7. Fisher M (2003) Prevention of marovascular complications. Eur Heart J 5 (Suppl B): 21-26
8. UK Prospective Diabetes Study (UKPD5) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865
9. Diabetes Atherosclerosis Intervention Study Investigators (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905-910
10. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N (2001) Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322: 15-18
11. Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314: 1512-1515
12. Diaz R, Paolasso EA, Piegas LS et al. (1998) Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98: 2227-2234
13. Stein B, Weintraub WS, Gebhart SP et al. (1995) Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91: 979-989
14. Van Belle E, Bauters C, Hubert E et al. (1997) Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 96: 1454-1460
15. Tschöpe D, Driesch E, Schwippert B, Lampeter EF (1997). Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia 40: 573-577
16. Meier-Ewert HK, Nesto RW (2002) Targeting the use of glycoprotein IIb/IIIa antagonists - the diabetic patient. Rev Cardiovasc Med 3 (Suppl 1): 20-27
17. Regar E, Serruys PW, Bode C et al., RAVEL Study Group (2002) Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106: 1949-1956
18. Corr LA, Stables R (2003) Managing heart disease. Coronary revascularization: knife or catheter. Eur Heart J 5 (Suppl B): 43-48
19. Zarich SW, Nesto RW (1989) Diabetic cardiomyopathy. Am Heart J 118: 1000-1012
20. Grossman E, Messereli FH (1996) Diabetic and hypertensive heart disease. Ann Intern Med 125: 304-310
21. Ferrara R, Guardigli, Ferrari R (2003) Undestanding patient needs myocardial metabolism: the diabetic heart. Eur Heart J 5 (Suppl B): 15-18
22. Williamson JR, Chang K, Frangos M et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813
23. Watschinger B, Brunner C,Wagner A, Schnack C, Prager R,Weissel M, Burghuber OC (1993) Left ventricular diastolic impairment in type 1 diabetic patients with microalbuminuria. Nephron 63: 145-151
24. Poirier P, Garneau C, Bogaty P et al. (2000) Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus. Am J Cardiol 85: 473-477
25. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98: 33-39
26. Fischer M, Baessler A, Hense HW et al. (2003) Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 24: 320-328
27. Romanens M, Fankhauser S, Saner B, Michaud L, Saner H (1999) No evidence for systolic or diastolic left ventricular dysfunction at rest in selected patients with longterm type I diabetes mellitus. Eur J Heart Fall 1: 169-175
28. Airaksinen KE, Koistinen MJ, Ikaheimo MJ et al. (1989) Augmentation of atrial contribution to left ventricular filling in IDDM subjects as assessed by Doppler echocardiography. Diabetes Care 12: 159-161
29. Paillole C, Dahan M, Paycha F, Solal AC, Passa P, Gourgon R (1989) Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. Am J Cardiol 64: 1010-1016
30. Zile MR, Brutsert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 19:1387-1393
31. Zile MR, Brutsaert DL (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105: 1503-1508
32. Paulus WJ (2000) Beneficial effects of nitric oxide on cardiac diastolic function: "the flip side of the coin". Heart Fail Rev 5: 337-344
33. Abe T, Ohga Y, Tabayashi N et al (2002) Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart 282: H138-148
34. Willenheimer RB, Erhardt LR, Nilsson H, Lilja B, Juul-Moller S, Sundkvist G (1998) Parasympathetic neuropathy associated with left ventricular diastolic dysfunction in patients with insulin-dependent diabetes mellitus. Scand Cardiovasc J 32:17-22
35. Mizushige K,Yao L, Noma T et al (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage ofa type II diabetic rat model. Circulation 29: 899-907
36. Brilla CG, Rupp H, Funck R, Maisch B (1995) The reninangiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 16 (Suppl O): 107-109
37. Tschöpe C, Schultheiss HP (2002) Diastolische Dysfunktion. Was diagnostisch nötig und therapeutisch möglich ist. Cardiovasc 2: 35-39
38. Krum H, Gilbert R (2001) Management ofthe heart failure patient with diabetes. Medicographio 32: 129-134
39. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259
40. Packer M, Poole-Wilson PA et al.(1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100: 212-238
41. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444
42. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 34: 709-717
43. Cosin J, Diez J (2002) Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507-513
44. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336: 525-533
45. Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403-1411
46. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylurease or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
47. Gilbert RE, Cooper ME, Krum H (1998) Drug administration in patients with diabetes mellitus. Safety considerations. Drug Saf 18: 441-455
48. He Z,Rask-Madsenn C, King GL (2003) Managing heart disease. Mechansims of cardiovascular complications in diabetes and potential new pharmacological therapies. Eur Heart J S (Suppl B): 51-57
49. Lonn E, Yusuf S, Hoogwerf B et al. (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-1927
50. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M (2001) Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage ofa type II diabetic rat. J Cardiovasc Pharmacol 38: 868-874
51. Stitt A, Gardiner TA, Alderson NL et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832
52. Doggrell SA (2001) ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure. Exp Opin Invest Drugs 10: 981-983
53. Kuwahara F, Kai H,Tokuda K, Kai M,Takeshita A, Egashira K, Imaizumi T (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130-135